Industry Strength Score
10/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
INVIVO THERAPEUTICS HOLDINGS (NVIV) Stock Price & Overview
NASDAQ:NVIV • US46186M6057
Current stock price
0.3207 USD
-0.17 (-34.28%)
At close:
0.231 USD
-0.09 (-27.97%)
After Hours:
The current stock price of NVIV is 0.3207 USD. Today NVIV is down by -34.28%. In the past month the price decreased by -58.69%. In the past year, price decreased by -84.43%.
NVIV Key Statistics
52-Week Range0.222 - 2.16
Current NVIV stock price positioned within its 52-week range.
1-Month Range0.222 - 1.05
Current NVIV stock price positioned within its 1-month range.
- Market Cap
- 997.377K
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.52
- Dividend Yield
- N/A
NVIV Stock Performance
Today
-34.28%
1 Week
+44.46%
1 Month
-58.69%
3 Months
-53.52%
Longer-term
6 Months -71.62%
1 Year -84.43%
2 Years -95.80%
3 Years -98.88%
5 Years -99.97%
10 Years N/A
NVIV Stock Chart
NVIV Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to NVIV. When comparing the yearly performance of all stocks, NVIV is a bad performer in the overall market: 98.27% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
NVIV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NVIV. NVIV has a great financial health rating, but its profitability evaluates not so good.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NVIV Earnings
Next Earnings DateN/A
Last Earnings DateAug 9, 2023
PeriodQ3 / 2023
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
NVIV Forecast & Estimates
Analysts
Analysts85.71
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
NVIV Financial Highlights
Over the last trailing twelve months NVIV reported a non-GAAP Earnings per Share(EPS) of -3.52. The EPS increased by 56.05% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-9.33M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -97.39% | ||
| ROE | -104.6% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%56.06%
Sales Q2Q%N/A
EPS 1Y (TTM)56.05%
Revenue 1Y (TTM)N/A
NVIV Ownership
Ownership
Inst Owners0.76%
Shares3.11M
Float2.77M
Ins Owners557.87%
Short Float %N/A
Short RatioN/A
NVIV Industry Overview
NVIV operates in the Health Care Equipment sub-industry within the Health Care sector. This group contains 127 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
61/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
13%
Outperformed 13% of sub-industries
3 Month Rank
10%
Outperformed 10% of sub-industries
6 Month Rank
10%
Outperformed 10% of sub-industries
Industry Fundamentals & Breadth
- Members
- 127
- New Highs
- 2.4%
- New Lows
- 13.4%
- Average ROE
- 17.1%
- Average Profit Margin
- 20.3%
- Average Operating Margin
- 22.5%
- Average P/E
- 28.2
- Average Fwd P/E
- 26.5
- Average Debt/Equity
- 0.5
NVIV Competitors/Peers
The largest stocks on the US markets in the "Health Care Equipment" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | 39.02 | 161.187B | ||
| ABT | ABBOTT LABORATORIES | 14.43 | 158.701B | ||
| SYK | STRYKER CORP | 20.96 | 120.688B | ||
| BSX | BOSTON SCIENTIFIC CORP | 14.61 | 84.935B | ||
| EW | EDWARDS LIFESCIENCES CORP | 24.67 | 46.827B | ||
| IDXX | IDEXX LABORATORIES INC | 37.7 | 43.972B | ||
| BDX | BECTON DICKINSON AND CO | 10.82 | 41.376B | ||
| RMD | RESMED INC | 17.38 | 30.874B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 10.63 | 27.142B | ||
| DXCM | DEXCOM INC | 23.33 | 22.153B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 9.01 | 15.499B | ||
| PEN | PENUMBRA INC | 64.01 | 12.772B | ||
| GMED | GLOBUS MEDICAL INC - A | 19.75 | 11.874B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NVIV
Company Profile
Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2006-11-14. The firm's Neuro-Spinal Scaffold implant is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. The company is intended to promote appositional, or side-by-side, healing by supporting the surrounding tissue after injury, minimizing the expansion of areas of necrosis, and providing a biomaterial substrate for the body's own healing/repair processes following injury. The company is composed of two biocompatible and bioresorbable polymers that are cast to form a porous investigational product: Poly lactic-co-glycolic acid and Poly-L-Lysine. Poly lactic-co-glycolic acid is a polymer that is used in resorbable sutures and provides biocompatible support for Neuro-Spinal Scaffold implants and Poly-L-Lysine is a positively charged polymer used to coat surfaces.
Company Info
IPO: 2006-11-14
INVIVO THERAPEUTICS HOLDINGS
Building 1400 East 4Th Floor, One Kendall Square
Cambridge MASSACHUSETTS 02139 US
CEO: Richard Toselli
Employees: 6
Phone: 16178635524
INVIVO THERAPEUTICS HOLDINGS / NVIV FAQ
What does NVIV do?
Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2006-11-14. The firm's Neuro-Spinal Scaffold implant is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. The company is intended to promote appositional, or side-by-side, healing by supporting the surrounding tissue after injury, minimizing the expansion of areas of necrosis, and providing a biomaterial substrate for the body's own healing/repair processes following injury. The company is composed of two biocompatible and bioresorbable polymers that are cast to form a porous investigational product: Poly lactic-co-glycolic acid and Poly-L-Lysine. Poly lactic-co-glycolic acid is a polymer that is used in resorbable sutures and provides biocompatible support for Neuro-Spinal Scaffold implants and Poly-L-Lysine is a positively charged polymer used to coat surfaces.
What is the current price of NVIV stock?
The current stock price of NVIV is 0.3207 USD. The price decreased by -34.28% in the last trading session.
Does INVIVO THERAPEUTICS HOLDINGS pay dividends?
NVIV does not pay a dividend.
What is the ChartMill technical and fundamental rating of NVIV stock?
NVIV has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in INVIVO THERAPEUTICS HOLDINGS be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NVIV.
What is INVIVO THERAPEUTICS HOLDINGS worth?
INVIVO THERAPEUTICS HOLDINGS (NVIV) has a market capitalization of 997.38K USD. This makes NVIV a Nano Cap stock.